Trial intelligence / Profile preview

Weekly oxaliplatin + capecitabine with radiotherapy before surgery in locally advanced rectal cancer

2004-004475-12Phase 2Completed

Sponsor
Spanish Cooperative Group for Digestive Tumour Therapy
Start
Apr 2006
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of oxaliplatin and capecitabine in rectal adenocarcinoma, sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Pathological response rate. Started Apr 2006; status: completed.

02

Drugs

oxaliplatincapecitabine
03

Conditions

rectal adenocarcinoma

Beyond the preview

Go deeper on 2004-004475-12.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-004475-12.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call